The next decade of vaccines: Societal and scientific challenges

The Lancet

Volumn 378, Issue 9788, 2011, Pages 348-359

  Moxon, E Richard ^a   Siegrist, Claire Anne ^b,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; DIPHTHERIA VACCINE; GLYCOCONJUGATE VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; MATERNAL ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; MENINGITIS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE;

ADAPTIVE IMMUNITY; ADVERSE OUTCOME; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTIGENIC VARIATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC DISEASE; DENGUE; DIPHTHERIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; INFLUENZA B; INNATE IMMUNITY; LYMPHATIC DRAINAGE; MALARIA; MALARIA FALCIPARUM; MASS IMMUNIZATION; MEASLES; MEMORY CELL; MENINGITIS; MICROBIAL DIVERSITY; MICROBIAL IMMUNITY; MICROBIAL POPULATION DYNAMICS; MUMPS; NEISSERIA MENINGITIDIS; NONHUMAN; PANDEMIC; PHARMACOGENOMICS; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REVIEW; RUBELLA; STREPTOCOCCUS PNEUMONIA; TETANUS; VACCINE PRODUCTION; YELLOW FEVER;

EID: 79960713332     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60407-8     Document Type: Review

References (89)

1. A Craig, A Scherf Antigenic variation 2003 Academic Press London 432
2. R Rappuoli, S Black, PH Lambert Vaccine discovery and translation of new vaccine technology Lancet 2011 10.1016/S0140-6736(11)60440-6 published online June 9.
3. J Smith, M Lipsitch, JW Almond Vaccine production, distribution, access, and uptake Lancet 2011 10.1016/S0140-6736(11)60478-9 published online June 9.
4. http://www.researchandmarkets.com/ (accessed Feb 11, 2011).
5. OS Levine, DE Bloom, T Cherian et al. The future of immunisation policy, implementation, and financing Lancet 2011 10.1016/S0140-6736(11)60406-6 published online June 9.
6. Population Division of UN Department of Economic and Social Affairs World population prospects: the 2008 revision http://www.un.org/esa/population/ publications/popnews/Newsltr-87.pdf June, 2009 (accessed April 1, 2011).
7. US Institute of Medicine Stratton K, Gable A, Shetty P, McCormick M, eds. Immunization safety review: measles-mumps-rubella vaccine and autism http://www.path.org/vaccineresources/files/Imm-Saf-Rev-IOM.pdf 2001 (accessed April 1, 2011).
8. AB Sabin, WA Hennessen, J Winsser Studies on variants of poliomyelitis virus: I. Experimental segregation and properties of avirulent variants of three immunologic types J Exp Med 99 1954 551 576
9. S Jegouic, ML Joffret, C Blanchard et al. Recombination between polioviruses and co-circulating Coxsackie A viruses: role in the emergence of pathogenic vaccine-derived polioviruses PLoS Pathog 5 2009 e1000412
10. JL Schulman, ED Kilbourne Independent variation in nature of hemagglutinin and neuraminidase antigens of influenza virus: distinctiveness of hemagglutinin antigen of Hong Kong-68 virus Proc Natl Acad Sci USA 2 1969 326 333
11. CT Dobzhansky Nothing in biology makes sense except in the light of evolution Am Biol Teach 35 1973 125 129
12. M Pittman Variation and type specificity in the bacterial species Hemophilus influenzae J Exp Med 53 1931 471 492
13. DC Turk, JR May Haemophilus influenzae: its clinical importance 1967 English Universities Press London 1 134
14. S Ladhani, ME Ramsay, M Chandra, MP Slack for EU-IBIS No evidence for Haemophilus influenzae serotype replacement in Europe after introduction of the Hib conjugate vaccine Lancet Infect Dis 8 2008 275 276 (Pubitemid 351615751)
15. D Pace, AJ Pollard, NE Messonier Quadrivalent meningococcal conjugate vaccines Vaccine 27 suppl 2 2009 B30 B41
16. LH Harrison, CL Trotter, ME Ramsay Global epidemiology of meningococcal disease Vaccine 27 suppl 2 2009 B51 B63
17. P Boisier, P Nicolas, S Djibo et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger Clin Infect Dis 44 2007 657 663
18. J Finne, M Leinonen, PH Mäkelä Antigenic similarities between brain components and bacteria causing meningitis: implications for vaccine development and pathogenesis Lancet 322 1983 355 357 (Pubitemid 13028927)
19. DM Granoff Review of meningococcal group B vaccines Clin Infect Dis 50 suppl 2 2010 S54 S65
20. WP Hausdorff, G Siber, PR Paradiso Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children Lancet 357 2001 950 952 (Pubitemid 32247290)
21. CG Whitney, MM Farley, J Hadler et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine N Engl J Med 348 2003 1737 1746 (Pubitemid 36514704)
22. J Eskola, T Kilpi, A Palmu for the Finnish Otitis Media Study Group Efficacy of a pneumococcal conjugate vaccine against acute otitis media N Engl J Med 344 2001 403 409 (Pubitemid 32128672)
23. WP Hanage Serotype-specific problems associated with pneumococcal conjugate vaccination Future Microbiol 3 2008 23 30 (Pubitemid 351385948)
24. R Malley Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development J Mol Med 88 2010 135 142
25. S Gupta, RM Anderson Population structure of pathogens: the role of immune selection Parasitol Today 15 1999 497 501 (Pubitemid 29525608)
26. MI Johnston, AS Fauci An HIV vaccine - challenges and prospects NEJM 359 2008 888 890
27. HW Virgin, BD Walker Immunology and the elusive AIDS vaccine Nature 464 2010 224 231
28. LM Walker, SK Phogat, PY Chan-Hui et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target Science 326 2009 285 289
29. DR Burton, RA Weiss AIDS/HIV. A boost for HIV vaccine design Science 329 2010 770 773
30. LM Walker, DR Burton Rational antibody-based HIV-1 vaccine design: current approaches and future directions Curr Opin Immunol 22 2009 358 366
31. X Wu, ZY Yang, Y Li et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 Science 329 2010 856 861
32. S Kyes, P Horrocks, C Newbold Antigenic variation at the infected red cell surface in malaria Annu Rev Microbiol 55 2001 673 707 (Pubitemid 32978120)
33. SI Hay, CA Guerra, AJ Tatem, PM Atkinson, RW Snow Urbanization, malaria transmission and disease burden in Africa Nat Rev Microbiol 3 2005 81 90 (Pubitemid 40028471)
34. SL Takala, CV Plowe Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria' Parasite Immunol 31 2009 560 573
35. MM Giuliani, J Adu-Bobie, M Comanducci et al. A universal vaccine for serogroup B meningococcus Proc Natl Acad Sci USA 103 2006 10834 10839 (Pubitemid 44148381)
36. MG Guzman, SB Halstead, H Artsob et al. Dengue: a continuing global threat Nat Rev Microbiol 8 suppl 2010 S7 S16
37. SB Halstead, EJ O'Rourke Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody J Exp Med 146 1977 201 217 (Pubitemid 8139503)
38. W Dejnirattisai, A Jumnainsong, N Onsirisakul et al. Cross-reacting antibodies enhance dengue virus infection in humans Science 328 2010 745 748
39. J Donnelly, D Medini, G Boccadifuoco et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines Proc Natl Acad Sci USA 107 2010 19490 19495
40. ME Ramsay, J McVernon, NJ Andrews, PT Heath, MP Slack Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method J Infect Dis 188 2003 481 485 (Pubitemid 37011798)
41. CP Farrington Estimation of vaccine effectiveness using the screening method Int J Epidemiol 22 1993 742 746 (Pubitemid 23247580)
42. C-A Siegrist Vaccine immunology SA Plotkin WA Orenstein PA Offit Vaccines 5th edn. 2008 Elsevier Philadelphia, PA 17 36
43. C-A Siegrist, R Aspinall B-cell responses to vaccination at the extremes of age Nat Rev Immunol 9 2009 185 194
44. L Manzoli, G Salanti, C De Vito, A Boccia, JPA Ioannidis, P Villari Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis Lancet Infect Dis 9 2009 482 492
45. S Khurana, W Chearwae, F Castellino et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus Sci Transl Med 2 2010 15ra5
46. W Olszewska, OE Obeid, MW Steward Protection against measles virus-induced encephalitis by anti-mimotope antibodies: the role of antibody affinity Virology 272 2000 98 105 (Pubitemid 30429433)
47. H Mouquet, JF Scheid, MJ Zoller et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation Nature 467 2010 591 595
48. Safe Injection Global Network WHO Report of the Safe Injection Global Network 2010 meeting http://www.who.int/injection-safety/toolbox/sign2010- meeting.pdf November, 2010 (accessed May 11, 2011).
49. M Mutsch, W Zhou, P Rhodes et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland N Engl J Med 350 2004 896 903 (Pubitemid 38252537)
50. DJ Lewis, Z Huo, S Barnett et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin PLoS One 4 2009 e6999
51. B Malik, AK Goyal, S Mangal, F Zakir, SP Vyas Implication of gut immunology in the design of oral vaccines Curr Mol Med 10 2010 47 70
52. JF Nicolas, B Guy Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice Expert Rev Vaccines 7 2008 1201 1214
53. MR Prausnitz, JA Mikszta, M Cormier, AK Andrianov Microneedle-based vaccines Curr Top Microbiol Immunol 333 2009 369 393
54. CD Rinaudo, JL Telford, R Rappuoli, KL Seib Vaccinology in the genome era J Clin Invest 119 2009 2515 2525
55. DC Palmer, NP Restifo Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function Trends Immunol 30 2009 592 602
56. CK Baumgartner, LP Malherbe Regulation of CD4 T-cell receptor diversity by vaccine adjuvants Immunology 130 2010 16 22
57. E Hammarlund, MW Lewis, SG Hansen et al. Duration of antiviral immunity after smallpox vaccination Nat Med 9 2003 1131 1137 (Pubitemid 37173696)
58. F Castellino, G Galli, G Del Giudice, R Rappuoli Generating memory with vaccination Eur J Immunol 39 2009 2100 2105
59. Kasturi SP, Skountzou I, Albrecht RA, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature; 470: 543-47.
60. ME Pichichero Booster vaccinations: can immunologic memory outpace disease pathogenesis? Pediatrics 124 2009 1633 1641
61. LA Jackson, EN Janoff Pneumococcal vaccination of elderly adults: new paradigms for protection Clin Infect Dis 47 2008 1328 1338
62. CL Trotter, MC Maiden Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs Expert Rev Vaccines 8 2009 851 861
63. V Gîlca, B Duval, N Boulianne, R Dion, G De Serres Impact of the Quebec school-based hepatitis B immunization program and potential benefit of the addition of an infant immunization program Pediatr Infect Dis J 25 2006 372 374
64. A Bekker, C Chou, HH Bernstein Update on universal annual influenza immunization recommendations for children Curr Opin Pediatr 21 2009 122 126
65. SA Cohen, KK Chui, EN Naumova Influenza vaccination in young children reduces influenza-associated hospitalizations in older adults, 2002-2006 J Am Geriatr Soc 59 2011 327 332
66. R Bayer The continuing tensions between individual rights and public health. Talking point on public health versus civil liberties EMBO Rep 8 2007 1099 1103 (Pubitemid 350201723)
67. O Levy Innate immunity of the newborn: basic mechanisms and clinical correlates Nat Rev Immunol 7 2007 379 390 (Pubitemid 46674489)
68. RB Belshe, KM Edwards, T Vesikari et al. Live attenuated versus inactivated influenza vaccine in infants and young children N Engl J Med 356 2007 685 696
69. R Prymula, C-A Siegrist, R Chlibek et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials Lancet 374 2009 1339 1350
70. S Sambhara, JE McElhaney Immunosenescence and influenza vaccine efficacy Curr Top Microbiol Immunol 333 2009 413 429
71. T Jefferson, C Di Pietrantonj, LA Al-Ansary, E Ferroni, S Thorning, RE Thomas Vaccines for preventing influenza in the elderly Cochrane Database Syst Rev 2 2010 CD004876.
72. A Huss, P Scott, AE Stuck, C Trotter, M Egger Efficacy of pneumococcal vaccination in adults: a meta-analysis CMAJ 180 2009 48 58
73. SA Moberley, J Holden, DP Tatham, RM Andrews Vaccines for preventing pneumococcal infection in adults Cochrane Database Syst Rev 1 2008 CD000422.
74. WH Chen, BF Kozlovsky, RB Effros, B Grubeck-Loebenstein, R Edelman, MB Sztein Vaccination in the elderly: an immunological perspective Trends Immunol 30 2009 351 359
75. A Panda, F Qian, S Mohanty et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response J Immunol 184 2010 2518 2527
76. PO Lang, S Govind, WA Mitchell, C-A Siegrist, R Aspinall Vaccine effectiveness in older individuals: what has been learned from the influenza-vaccine experience Ageing Res Rev 2010 10.1016/j.arr.2010.09.005 published online Sept 30.
77. GD Deans, HG Stiver, JE McElhaney Influenza vaccines provide diminished protection but are cost-saving in older adults J Intern Med 267 2010 220 227
78. F Mosca, E Tritto, A Muzzi et al. Molecular and cellular signatures of human vaccine adjuvants Proc Natl Acad Sci USA 105 2008 10501 10506
79. RS Fujinami, MG von Herrath, U Christen, JL Whitton Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease Clin Microbiol Rev 19 2006 80 94 (Pubitemid 43157648)
80. PT Heath Haemophilus influenzae type b conjugate vaccines: a review of efficacy data Pediatr Infect Dis J 17 suppl 1998 S117 S122
81. M Patel, AL Shane, UD Parashar, B Jiang, JR Gentsch, RI Glass Oral rotavirus vaccines: how well will they work where they are needed most? J Infect Dis 200 suppl 1 2009 S39 S48
82. A Alcaïs, L Abel, JL Casanova Human genetics of infectious diseases: between proof of principle and paradigm J Clin Invest 119 2009 2506 2514
83. S De Flora, P Bonanni The prevention of infection-associated cancers Carcinogenesis 2011 10.1093/carcin/bgr054 published online March 24.
84. GA Poland, IG Ovsyannikova, RM Jacobson Application of pharmacogenomics to vaccines Pharmacogenomics 10 2009 837 852
85. A Sette, R Rappuoli Reverse vaccinology: developing vaccines in the era of genomics Immunity 33 2010 530 541
86. B Pulendran, S Li, HI Nakaya Systems vaccinology Immunity 33 2010 516 529
87. US Centers for Disease Control and Prevention Influenza vaccination coverage among children and adults - United States, 2008-09 influenza season MMWR Morb Mortal Wkly Rep 58 2009 1091 1095
88. P Bonanni Vaccination and risk groups: how can we really protect the weakest? Hum Vaccin 3 2007 217 219 (Pubitemid 47598181)
89. J Chow, SM Lee, Y Shen, A Khosravi, SK Mazmanian Host-bacterial symbiosis in health and disease Adv Immunol 107 2010 243 274